title: Creutzfeldt-Jakob disease after pituitary-derived human growth hormone therapy: two cases with valine 129 homozygous genotype.
authors.affiliation: Clinique neurologique, Hôpital Beaujon, Clichy, France.
authors.forename: C
authors.initials: C
authors.lastname: Masson
authors.forename: I
authors.initials: I
authors.lastname: Delalande
authors.forename: J P
authors.initials: JP
authors.lastname: Deslys
authors.forename: D
authors.initials: D
authors.lastname: Hénin
authors.forename: C
authors.initials: C
authors.lastname: Fallet-Bianco
authors.forename: D
authors.initials: D
authors.lastname: Dormont
authors.forename: D
authors.initials: D
authors.lastname: Leys
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D007562:Creutzfeldt-Jakob Syndrome / Q000139:chemically induced* / Q000235:genetics; D005838:Genotype; D013006:Growth Hormone / Q000009:adverse effects* / Q000172:deficiency / Q000627:therapeutic use; D006720:Homozygote; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy; D008297:Male; D018620:PrPSc Proteins; D011328:Prions / Q000235:genetics*; D014633:Valine
chemical_list: D018620:PrPSc Proteins; D011328:Prions; D013006:Growth Hormone; D014633:Valine